Innovating Works

Stichting Sanquin Bloedvoorziening

Desconocido
IgG4-TREAT: Systematic study of IgG4-autoimmune diseases to develop new treatment strategies Stichting Sanquin Bloedvoorziening participó en un HORIZON EUROPE: HORIZON-MSCA-2022-DN-01 IgG4-autoimmune diseases (IgG4-AID) are rare but collectively correspond to a significant group of devastating diseases affecting many diffe...
2023-07-07 - 2027-08-31 | Financiado
IMMUTOL: ADVANCED ANTIGEN-SPECIFIC DENDRITIC CELL-BASED THERAPY TO RE-ESTABLISH TOLERANCE IN IMMUNE-MEDIATED... Stichting Sanquin Bloedvoorziening participó en un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Autoimmune diseases are currently treated with immunosuppressive and supportive therapies, which dampen inflammation, but do not stop the ca...
2023-04-14 - 2027-04-30 | Financiado
M6ATCELL: Exploiting fundamental insights of m6A methylation on CD8 T cell differentiation and function to boo... Stichting Sanquin Bloedvoorziening tramitó un HORIZON EUROPE: HORIZON-MSCA-2022-PF-01 Adoptive T cell therapies have revolutionised cancer treatment in some haematological tumours. Despite astounding advances, patients often r...
2023-03-27 - 2025-09-30 | Financiado
RBP-ReguNet: Deconstructing and Rewiring RNA RBP regulatory networks Stichting Sanquin Bloedvoorziening participó en un HORIZON EUROPE: HORIZON-MSCA-2021-DN-01 RNA-binding proteins (RBPs) are critical regulators of gene expression programs. They regulate all aspects of RNA life, including transcript...
2022-07-14 - 2027-02-28 | Financiado
COVID-RED: COVID 19 infections Remote Early Detection Stichting Sanquin Bloedvoorziening participó en un H2020: H2020-JTI-IMI2-2020-21-single-stage In this project, we will evaluate the use and performance of a CE-marked device (wearable), which uses sensors to measure breathing rate, pu...
2020-10-16 - 2022-12-31 | Financiado
SUPPORT-E: SUPporting high quality evaluation of COVID 19 convalescent Plasma thrOughoutT Europe Stichting Sanquin Bloedvoorziening participó en un H2020: Coronavirus disease 19 (COVID-19) is provoking the greatest global health crisis of this generation. With no vaccine or specific antiviral t...
2020-09-02 - 2025-12-31 | Financiado
SciFiMed: Screening of inFlammation to enable personalized Medicine Stichting Sanquin Bloedvoorziening participó en un H2020: H2020-FETOPEN-2018-2020 This transdisciplinary project will combine fundamental immunological research with novel nanomaterial-based biosensor development translate...
2020-05-26 - 2024-12-31 | Financiado
EDUC8: Early Stage Researchers EDUCational Program on Factor VIII Immunogenicity Stichting Sanquin Bloedvoorziening participó en un H2020: H2020-MSCA-ITN-2019 The development of anti-drug antibodies is the major complication of treatment with biotherapeutics. This is particularly true of patients w...
2019-12-17 - 2024-09-30 | Financiado
INsTRuCT: INnovative Training in Myeloid Regulatory Cell Therapy Stichting Sanquin Bloedvoorziening participó en un H2020: H2020-MSCA-ITN-2019 Cell therapy is an active area of immunological research and represents a highly innovative and rapidly expanding sector of pharmaceutical i...
2019-08-19 - 2024-06-30 | Financiado
EVIDENCE: Erythrocytes properties and viability in dependence of flow and extra cellular environment Stichting Sanquin Bloedvoorziening participó en un H2020: H2020-MSCA-ITN-2019 After exiting the bone marrow, reticulocytes mature to form red blood cells (RBCs) which are highly adapted cells Red blood cells (RBCs) tra...
2019-08-19 - 2023-12-31 | Financiado
PRinTERs: Post transcriptional regulation of effector function in T cells by RNA binding proteins Stichting Sanquin Bloedvoorziening tramitó un H2020: ERC-2018-COG CD8+ T cells are critical to fight infections and to clear tumor cells through the production of inflammatory cytokines and cytotoxic molecu...
2019-02-28 - 2024-08-31 | Financiado
TC-Evo: Molecular and functional evolution of human CD8 T cell repertoires Stichting Sanquin Bloedvoorziening tramitó un H2020: H2020-MSCA-IF-2017 Humans are equipped with a sophisticated immune system, especially adaptive immunity, which is characterized by the finest antigen specifici...
2018-04-23 - 2021-07-13 | Financiado
RESTORE: NEURONAL SELF RENEWAL BY ANTIGEN SPECIFIC TOLERIZATION IN MULTIPLE SCLEROSIS REINSTALLING THE BALANC... Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the central nervous system for which no cure is currently available....
2017-11-21 - 2023-06-30 | Financiado
GlySign: Exploitation of Glycosylation Signatures for Precision Medicine Stichting Sanquin Bloedvoorziening participó en un H2020: H2020-MSCA-ITN-2016 GlySign is a research training network for the translation of glycomic clinical biomarkers for Precision Medicine (PM). Complex, distinctive...
2016-07-06 - 2020-09-30 | Financiado
RELEVANCE: Regulation of red cell life span erythropoiesis survival senescence and clearance Stichting Sanquin Bloedvoorziening participó en un H2020: H2020-MSCA-ITN-2015 Anaemia is the most common pathological condition affecting 1.6 billion individuals worldwide. It thus presents a serious health care proble...
2015-08-03 - 2019-11-30 | Financiado
PROFILE: Innovative training network Immunoprofile directed stratification of patients with the autoimmune d... Stichting Sanquin Bloedvoorziening participó en un H2020: H2020-MSCA-ITN-2015 The PROFILE Innovative European Industrial Doctoral programme will develop improved tools for stratification of patients with the autoimmune...
2015-08-03 - 2019-09-30 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.